Intratumoral delivery of shRNA targeting cyclin D1 attenuates pancreatic cancer growth

被引:15
作者
Deharvengt, S. J. [1 ,2 ,3 ]
Gunn, J. R. [1 ,2 ,3 ]
Pickett, S. B. [1 ,2 ,3 ]
Korc, M. [1 ,2 ,3 ]
机构
[1] Norris Cotton Ctr, Dept Med, Lebanon, NH USA
[2] Norris Cotton Ctr, Dept Pharmacol & Toxicol, Lebanon, NH USA
[3] Dartmouth Med Sch, Lebanon, NH USA
关键词
cyclin D1; pancreatic cancer; shRNA; lentivirus; VIVO GENE DELIVERY; IN-VIVO; ENHANCES TUMORIGENICITY; ESOPHAGEAL CANCER; EXPRESSION; CELLS; OVEREXPRESSION; ANTISENSE; INHIBITION; ADENOCARCINOMAS;
D O I
10.1038/cgt.2009.75
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
The aim of this study was to assess the biological consequences of cyclin D1 silencing in pancreatic cancer cells. A replication-defective lentivirus based small hairpin RNA (shRNA) system targeting cyclin D1 caused a marked reduction in cyclin D1 protein levels in ASPC-1 and BxPC3 pancreatic cancer cell lines in conjunction with decreased cell growth and invasiveness in vitro. Moreover, a single intratumoral injection of the recombinant lentivirus targeting cyclin D1 attenuated the growth of pre-existing tumors arising from two distinct cell lines. This attenuated growth correlated with decreased proliferation and angiogenesis, as well as attenuated vascular endothelial growth factor expression. It is concluded that lentivirus-delivered shRNA targeting cyclin D1 suppresses the growth, invasiveness, tumorigenicity and pro-angiogenic potential of human pancreatic cancer cells, thereby raising the possibility that intratumoral injections of viruses targeting cyclin D1 could provide a new therapeutic approach in pancreatic ductal adenocarcinoma. Cancer Gene Therapy (2010) 17, 325-333; doi:10.1038/cgt.2009.75; published online 23 October 2009
引用
收藏
页码:325 / 333
页数:9
相关论文
共 46 条
[1]
Adjuvant therapy for surgically resected pancreatic adenocarcinoma [J].
Abbruzzese, James L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (09) :1066-1067
[2]
Biomedicine - Lentiviral vectors - the promise of gene therapy within reach? [J].
Amado, RG ;
Chen, ISY .
SCIENCE, 1999, 285 (5428) :674-676
[3]
Arato-Ohshima T, 1999, INT J CANCER, V83, P387, DOI 10.1002/(SICI)1097-0215(19991029)83:3<387::AID-IJC15>3.0.CO
[4]
2-O
[5]
Arber N, 1997, CANCER RES, V57, P1569
[6]
CYCLIN D1 IS A NUCLEAR-PROTEIN REQUIRED FOR CELL-CYCLE PROGRESSION IN G(1) [J].
BALDIN, V ;
LUKAS, J ;
MARCOTE, MJ ;
PAGANO, M ;
DRAETTA, G .
GENES & DEVELOPMENT, 1993, 7 (05) :812-821
[7]
BERNARDS R, 1999, BIOCHIM BIOPHYS ACTA, V1424, P17
[8]
Acetylation control of the retinoblastoma tumour-suppressor protein [J].
Chan, HM ;
Krstic-Demonacos, M ;
Smith, L ;
Demonacos, C ;
La Thangue, NB .
NATURE CELL BIOLOGY, 2001, 3 (07) :667-674
[9]
Induction and expression of cyclin D3 in human pancreatic cancer [J].
Ebert, MPA ;
Hernberg, S ;
Fei, G ;
Sokolowski, A ;
Schulz, HU ;
Lippert, H ;
Malfertheiner, P .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (07) :449-454
[10]
Minireview: Cyclin D1: Normal and abnormal functions [J].
Fu, MF ;
Wang, CG ;
Li, ZP ;
Sakamaki, T ;
Pestell, RG .
ENDOCRINOLOGY, 2004, 145 (12) :5439-5447